Novartis to Buy Cancer Diagnostic Specialist Genoptix for $470 Million (NVS)

By
A A A
Share |

Swiss healthcare products maker Novartis AG ( NVS ) on Monday said it would buy U.S.-based cancer diagnostic specialist Genoptix ( GXDX ) for $470 million in cash.

The $25 per-share asking price represents a healthy 27% premium over Genoptix' Friday closing price of $19.76. Genoptix said its board of directors is recommending current shareholders accept the offer.

The move comes about six weeks after Novartis acquired the remaining stake in eye care company Alcon for $12.9 billion .


Novartis shares rose 27 cents, or +0.5%, in premarket trading Monday.

The Bottom Line
Shares of Novartis ( NVS ) have a 3.03% dividend yield, based on Friday's closing stock price of $56.42. The stock has technical support in the $52-$54 price area. If the shares can firm up, we see overhead resistance around the $60 price level.

Novartis AG ( NVS ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by Dividend.com


This article appears in: Investing , Stocks

Referenced Stocks: NVS

Dividend.com

Dividend.com

More from Dividend.com:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

41,145,449
  • $17.61 ▲ 0.46%
32,389,714
  • $112.37 ▼ 0.25%
28,917,271
  • $25.2228 ▲ 0.33%
27,346,295
  • $47.875 ▲ 0.75%
24,069,105
  • $6.98 ▲ 5.12%
23,810,456
  • $27.68 ▲ 0.11%
23,746,984
  • $36.42 ▼ 1.62%
21,305,371
  • $9.54 ▼ 5.26%
As of 12/19/2014, 11:37 AM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com